IL81841A - Crystalline,anhydrous sigma-form of 2-(4-(2-furoyl)-(2-piperazin)-1-yl)-4-amino-6,7-dimethoxyquinazoline hydrochloride and a process for its preparation - Google Patents

Crystalline,anhydrous sigma-form of 2-(4-(2-furoyl)-(2-piperazin)-1-yl)-4-amino-6,7-dimethoxyquinazoline hydrochloride and a process for its preparation

Info

Publication number
IL81841A
IL81841A IL81841A IL8184187A IL81841A IL 81841 A IL81841 A IL 81841A IL 81841 A IL81841 A IL 81841A IL 8184187 A IL8184187 A IL 8184187A IL 81841 A IL81841 A IL 81841A
Authority
IL
Israel
Prior art keywords
furoyl
piperazin
crystalline
amino
preparation
Prior art date
Application number
IL81841A
Other languages
English (en)
Other versions
IL81841A0 (en
Original Assignee
Heumann Pharma Gmbh & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Heumann Pharma Gmbh & Co filed Critical Heumann Pharma Gmbh & Co
Publication of IL81841A0 publication Critical patent/IL81841A0/xx
Publication of IL81841A publication Critical patent/IL81841A/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL81841A 1986-03-21 1987-03-10 Crystalline,anhydrous sigma-form of 2-(4-(2-furoyl)-(2-piperazin)-1-yl)-4-amino-6,7-dimethoxyquinazoline hydrochloride and a process for its preparation IL81841A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP86103925A EP0237608B1 (de) 1986-03-21 1986-03-21 Kristalline, wasserfreie Sigma -Form von 2-[4-(2-Furoyl-(2-piperazin)-1-yl]-4-amino-6,7-dimethoxychinazolinhydrochlorid und Verfahren zu ihrer Herstellung

Publications (2)

Publication Number Publication Date
IL81841A0 IL81841A0 (en) 1987-10-20
IL81841A true IL81841A (en) 1991-06-10

Family

ID=8194990

Family Applications (1)

Application Number Title Priority Date Filing Date
IL81841A IL81841A (en) 1986-03-21 1987-03-10 Crystalline,anhydrous sigma-form of 2-(4-(2-furoyl)-(2-piperazin)-1-yl)-4-amino-6,7-dimethoxyquinazoline hydrochloride and a process for its preparation

Country Status (19)

Country Link
US (1) US4816455B1 (id)
EP (1) EP0237608B1 (id)
JP (1) JPH0662615B2 (id)
KR (1) KR870008875A (id)
AR (1) AR242384A1 (id)
AT (1) ATE72244T1 (id)
AU (1) AU586318B2 (id)
CA (1) CA1240999A (id)
DE (1) DE3683760D1 (id)
DK (1) DK173283B1 (id)
ES (1) ES2009486A6 (id)
GR (1) GR870429B (id)
HU (1) HU200176B (id)
ID (1) ID810B (id)
IE (1) IE59913B1 (id)
IL (1) IL81841A (id)
NZ (1) NZ219644A (id)
PT (1) PT84496B (id)
ZA (1) ZA87966B (id)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5412095A (en) * 1993-04-29 1995-05-02 Abbott Laboratories Terazosin monohydrochloride and processes and intermediate for its production
US5504207A (en) * 1994-10-18 1996-04-02 Abbott Laboratories Process and intermediate for the preparation of terazosin hydrochloride dihydrate
EP0794178A4 (en) * 1994-11-25 1998-02-25 Nippon Chemiphar Co CHINAZOLIN DERIVATIVES
US5587377A (en) * 1995-10-24 1996-12-24 Invamed, Inc. Terazosin crystalline polymorph and pharmaceutical compositions thereof
DE59611417D1 (de) * 1996-12-20 2007-03-29 Heumann Pharma Gmbh & Co Neue polymorphe Form von Doxazosinmesylat (Form III)
EP0849265A1 (de) * 1996-12-20 1998-06-24 HEUMANN PHARMA GmbH Neue polymorphe Form von Doxazosin-Mesylat (Form II)
EP0849264A1 (de) * 1996-12-20 1998-06-24 HEUMANN PHARMA GmbH Neue polymorphe Form von doxazosinmesylat (Form I)
CA2566652C (en) 1998-06-19 2008-10-21 Teijin Limited Polymorphic modifications of 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazole-carboxylic acid and processes for the preparation thereof
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
CL2004001034A1 (es) 2003-05-14 2005-03-28 Teijin Pharma Ltd Formas cristalinas de acido 4-(1-((,etilbenzotiofen-3-il)me til)benzimidazol-2-iltio)butanoico; procedimiento de preparacion de las formas cristalinas; composicion farmaceutica; y su uso para el tratamiento de enfermedades inflamatorias, alergicas, r
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
JPWO2006052026A1 (ja) * 2004-11-12 2008-05-29 帝人ファーマ株式会社 ベンズイミダゾール誘導体の酸性塩及びその結晶
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
EP2540725A1 (de) 2006-05-04 2013-01-02 Boehringer Ingelheim International GmbH Polymorphe von 1-((4-Methyl-chinazolin-2-yl)methyl)-3-methyl-7-(2-butin-1-yl)-8-(3-(R)-amino-piperidin-1-yl)xanthin
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
WO2009024542A2 (en) * 2007-08-17 2009-02-26 Boehringer Ingelheim International Gmbh Purin derivatives for use in the treatment of fab-related diseases
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
NZ604091A (en) * 2008-08-15 2014-08-29 Boehringer Ingelheim Int Purin derivatives for use in the treatment of fab-related diseases
CN102149407A (zh) 2008-09-10 2011-08-10 贝林格尔.英格海姆国际有限公司 治疗糖尿病和相关病症的组合疗法
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
CN102256976A (zh) 2008-12-23 2011-11-23 贝林格尔.英格海姆国际有限公司 有机化合物的盐形式
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
KR20240090632A (ko) 2009-11-27 2024-06-21 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 dpp-iv 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
CN102946875A (zh) 2010-05-05 2013-02-27 贝林格尔.英格海姆国际有限公司 组合疗法
WO2011161161A1 (en) 2010-06-24 2011-12-29 Boehringer Ingelheim International Gmbh Diabetes therapy
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
US8883800B2 (en) 2011-07-15 2014-11-11 Boehringer Ingelheim International Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
JP6218811B2 (ja) 2012-05-14 2017-10-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Sirs及び/又は敗血症の治療に用いるdpp−4阻害薬としてのキサンチン誘導体
JP6224084B2 (ja) 2012-05-14 2017-11-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糸球体上皮細胞関連障害及び/又はネフローゼ症候群の治療に用いるdpp−4阻害薬としてのキサンチン誘導体
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
EP3110449B1 (en) 2014-02-28 2023-06-28 Boehringer Ingelheim International GmbH Medical use of a dpp-4 inhibitor
CN109310697A (zh) 2016-06-10 2019-02-05 勃林格殷格翰国际有限公司 利格列汀和二甲双胍的组合

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3511836A (en) 1967-12-13 1970-05-12 Pfizer & Co C 2,4,6,7-tetra substituted quinazolines
US4026894A (en) * 1975-10-14 1977-05-31 Abbott Laboratories Antihypertensive agents
US4092315A (en) * 1976-03-01 1978-05-30 Pfizer Inc. Novel crystalline forms of prazosin hydrochloride
GB1591490A (en) * 1977-08-04 1981-06-24 Abbott Lab 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-tetrahydrofuroyl)piperazine hydrochloride dihydrate
DE3375395D1 (en) * 1983-11-22 1988-02-25 Heumann Ludwig & Co Gmbh Process for the preparation of 4-amino-6,7-dimethoxy-2-(4-(furoyl-2)-piperazin-1-yl)-quinazoline and its physiologically acceptable salt
FI79107C (fi) * 1984-06-25 1989-11-10 Orion Yhtymae Oy Foerfarande foer framstaellning av stabil -form av prazosinhydroklorid.

Also Published As

Publication number Publication date
US4816455A (en) 1989-03-28
ZA87966B (en) 1987-08-04
DK139887D0 (da) 1987-03-18
DK173283B1 (da) 2000-06-13
DK139887A (da) 1987-09-22
EP0237608B1 (de) 1992-01-29
ID810B (id) 1996-07-15
PT84496A (de) 1987-04-01
ES2009486A6 (es) 1989-10-01
DE3683760D1 (de) 1992-03-12
IE870705L (en) 1987-09-21
HUT47101A (en) 1989-01-30
AR242384A1 (es) 1993-03-31
AU6870787A (en) 1987-09-24
IL81841A0 (en) 1987-10-20
HU200176B (en) 1990-04-28
NZ219644A (en) 1989-04-26
US4816455B1 (en) 1992-11-24
EP0237608A1 (de) 1987-09-23
JPS62226980A (ja) 1987-10-05
GR870429B (en) 1987-07-13
KR870008875A (ko) 1987-10-21
IE59913B1 (en) 1994-04-20
CA1240999A (en) 1988-08-23
AU586318B2 (en) 1989-07-06
JPH0662615B2 (ja) 1994-08-17
PT84496B (pt) 1989-11-10
ATE72244T1 (de) 1992-02-15

Similar Documents

Publication Publication Date Title
US4816455B1 (en) Crystalline,anhydrous sigma-form of 2-(4-(2-furoyl)-(2-piperazin)-1-yl)-4-amino-6,7-dimethoxy-quinoazoline hydrochloride and a process for its preparation
IL73267A (en) Anhydrous,stable,crystalline delta-form of prazosin hydrochloride and a process for its preparation
AR240698A1 (es) Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
NO177387C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive imidazo-kondenserte, 6-leddede, heterocykliske forbindelser
HUT45520A (en) Process for producing new quinoline derivatives and pharmaceutics comprising these compounds as active ingredient
DK8985A (da) 4-((bicyklisk heterocyclyl)-methyl og -hetero)-piperidin-derivater ogfremgangsmaade til fremstilling deraf
NZ218047A (en) Crystalline paroxetine hydrochloride, pharmaceutical compositions and intermediates
PL269091A1 (en) Method for manufacturing new pharmacologically active derivatives of catechine
NO941211D0 (no) Farmakologisk aktive pyrimidinforbindelser og fremgangsmåte for deres fremstilling
RO92610A (ro) Procedeu de preparare a unor 2-(2'-alchil-benzoil)-1,3-ciclohexandione
FI911411L (fi) Kiteinen, kidevedetön laktitoli ja menetelmä sen valmistamiseksi sekä sen käyttö
PH24749A (en) Piperidine compounds, pharmaceutical composition and method of use thereof
FI885153L (fi) Menetelmä terapeuttisesti aktiivisten 2',3'-dideoksi-2'-fluorinukleosidien valmistamiseksi
GB8801930D0 (en) Carding machine & method of carding
FI901775A7 (fi) Menetelmä uusien terapeuttisesti käyttökelpoisten tiourasiilijohdannaisten valmistamiseksi
GB2041932B (en) Method for producing 6,7-dimethoxy-4-amino-2-(4-(2-furoyl)-1-piper-azinyl) quinazoline hydrochloride
HUT45516A (en) Process for producing new benzothiazinone derivatives and pharmaceutics comprising such active ingredient
HUT46011A (en) Process for producing isoquinoline derivatives and pharmaceutics comprising these compounds as active ingredient
HUT49572A (en) Process for producing 2-(amino-alkyl-thio)-methyl-1,4-dihydropyridine derivatives and pharmaceutical compositions containing them
EP0435840A3 (en) Process for the preparation of 2-(2-furyl) ethanol amine
BG52091B2 (en) Method for the preparation of crystalline -form of 1-(4-amino-6-7-dimethoxyquinazolin-2-yl)-4-(2-furoyl)-piperazine hydrochloride
ZM3788A1 (en) Process of preparing 3-(2-(4-(4-fluorobenzoy)-1-piperidinyl)-ethyl)-2,4-(1h,3h)-quinazolinedione
IT1204336B (it) Processo per la preparazione di 2-(n-benzil-n-metilammino)-etil-metil1,4-diidro-2,6-dimetil-4-(3-nitrofenil)-3,5-piridin-dicarbossilato cloridrato
CS410788A1 (en) Method of n-(1-formamido-2,2,2-trichlorethyl)morpholine's crystalline modification production
CS600289A1 (en) Method of 2-(n,n-disubstituted)2,4-diaminoquinazolines production

Legal Events

Date Code Title Description
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXP Patent expired